1. Bristol-Myers Squibb is considered the leader in the immunotherapy market with its cancer drug Opdivo, which is expected to have annual sales of $11.1 billion by 2020. But Merck, Roche, and AstraZeneca may still have time to catch up. (Reuters)
2. McKesson said it will buy cancer-care company Vantage Oncology and oncology pharmacy-services firm Biologics, an oncology pharmacy services provider. The company will spend $1.2 billion in total on these acquisitions. (WSJ)
3. Bayer said Werner Baumann, its strategy officer, will take over as CEO in May. Bayer’s current CEO Marijn Dekkers requested that his contract end early. (AP)
4. Health economists are encouraging a national discussion that addresses whether the time gained from expensive new treatments is worth the cost to both patients and society. For the roughly 70 new drugs approved between 2002 and 2014 to treat solid tumors, the median improvement in survival was 2.1 months. (Stat)
5. Alfred Mann, 90, most recently chairman and founder of MannKind, the manufacturer that developed Afrezza, an inhaled insulin product, has died. He is remembered for investing in companies that developed the first rechargeable pacemaker and an artificial retina used by the blind. (LAT)
